

# Optimization of Gabapentin Release and Targeting Absorption, Through Incorporation into Alginate Beads

Pierre A. Hanna, Hassan M. Ghonaim\*, Shadeed Gad and Mamdouh M. Ghorab

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt.

## ABSTRACT

**Aims:** 1) To study the effect of some formulation variables on drug load, encapsulation efficiency, swelling ratio, mucoadhesion and drug release.  
2) Optimize the mucoadhesion capabilities for targeting drug absorption and release-controlling capabilities of alginate beads.

**Methodology:** alginate beads were prepared by dripping sodium alginate gel into calcium chloride solution and then dried overnight at ambient temperature. The effects of alginate concentration, cross linker concentration, cross linking time, volume of cross linking solution and drug/polymer ratio on drug load, encapsulation efficiency, swelling ratio, mucoadhesion and drug release were investigated. Formulae containing sodium lauryl sulfate (SLS), gabapentin-ethylcellulose solid dispersion, mixture of free drug and solid dispersion were prepared for modifying the drug release rate.

**Results:** Mucoadhesion of alginate beads was shown to be decreased upon adding SLS (30% after 8 hrs). Drug release was so fast (92.46% after 2 hrs). The incorporation of solid dispersion has led to well accepted mucoadhesion (74.44% after 8 hrs) as well as release properties (93.35% after 10 hrs) Beads containing mixtures of drug and ethylcellulose-drug solid dispersion showed acceptable mucoadhesion (74.44% after 8 hrs) and control of gabapentin release (93.35% after 10 hrs). Statistical analysis of variance between groups was performed using the one-way layout ANOVA with duplication. Significant differences in mean values were evaluated by Student's unpaired t test ( $p < 0.05$ ).

**Conclusion:** A finally optimized formula was suggested by incorporating a combination of solid dispersion and free gabapentin in alginate system to achieve burst release of gabapentin and hence fast effect (33.417% was released during the first 30 minutes in fasting-simulated conditions) and controlled release (91.217% after 6 hrs).

**Keywords:** Alginate, Control release, Targeting, Gabapentin, Sodium lauryl sulfate, Ethyl cellulose, Solid dispersion.

\* Tel/fax: +20643230741.

E-mail address: [hassan\\_ghonaim@pharm.suez.edu.eg](mailto:hassan_ghonaim@pharm.suez.edu.eg).

22 **1. INTRODUCTION**

23

24 Alginate is a natural polysaccharide found in all species of brown algae. It exists as a  
25 linear polymer consisting of  $\beta$ -D-(1 $\rightarrow$ 4) mannuronic acid (M) and  $\alpha$ -L-(1 $\rightarrow$ 4) guluronic acid  
26 (G) in varying proportions and sequential arrangement [1]. The homopolymer regions  
27 composed of M blocks and G blocks are interspersed with MG heteropolymeric regions.  
28 Alginate is a hydrophilic polymer that swells in the presence of water. Sodium alginate,  
29 which is the sodium salt of alginate, is soluble in water and can be cross-linked with  
30 divalent cations such as  $\text{Ca}^{2+}$  and  $\text{Zn}^{2+}$  and polyvalent ones to form an insoluble alginate.  
31 Calcium ion was found to bind selectively guluronic acid residues (GG) in a planar two-  
32 dimensional structure producing the so-called "egg box" structure [2]. The ratio of G to M  
33 residues was found to affect the release of drugs from calcium-cross-linked alginate systems  
34 [3].

35 Alginate systems were found to have a number of properties that are used to deliver DNA  
36 [4], locally deliver enzymes [5], immobilize enzymes [6], oral immunization [7], and to act as  
37 adenovirus vector [8].

38 The mucoadhesive properties of alginate emphasized its use as an efficient tool to improve  
39 oral mucoadhesion for increasing bioavailability of drugs [9] such as nifedipine HCl [10],  
40 gliclazide [11,12], and diltiazem HCl [13] and to control systemic absorption of some narrow  
41 absorption window (NAW) drugs.

42 Gabapentin is an orally available  $\gamma$ -aminobutyric acid analog which is used to control partial  
43 seizures in combination with other antiepileptic drugs [14]. It is one of the NAW drugs **since it**  
44 **is** actively absorbed from upper duodenal region via L-amino acid transporters [15].

45 The aim of this study was to evaluate the effect of formulation variables on alginate beads  
46 properties and **optimizing their drug targeting properties as well as release control profile**  
47 using gabapentin as a hydrophilic model drug.

48

49

50 **2. MATERIAL AND METHODS**

51

52 **2.1 Materials**

53 Sodium alginate was purchased from Sigma Aldrich, St. Louis, USA. Gabapentin was a gift  
54 from Delta Pharm, 10<sup>th</sup> of Ramadan city, Egypt. Calcium chloride dihydrate from VWR  
55 Scientific, West Chester, PA, USA. Sodium lauryl sulphate (SLS) from Aldrich, Milwaukee,  
56 WI, USA. The other chemicals used were all of analytical and HPLC grade.

57

58 **2.2 Methods**

59

60 **2.2.1 Preparation of calcium alginate mucoadhesive beads**

61 **Calcium alginate beads were prepared by ionotropic gelation.** The amounts of sodium  
62 alginate, concentration of calcium chloride solution and quantity of gabapentin used and the  
63 formulation **variables** of the beads are listed in table 1. **A gel solution of sodium alginate was**  
64 **made by hydrating** the proper amount of sodium alginate in deionized water and stirring till a  
65 clear gel solution is formed. **In separate vial,** gabapentin was dispersed evenly in deionized  
66 water and then added to the gel. A gentle and consistent mixing for about 5 **minutes.** **The**  
67 **formed gel containing the drug was then placed in a syringe pump (model M362, Sage**  
68 **Instruments, Orion Research Inc., Massachusetts, USA) then** introduced into calcium  
69 chloride solution by dripping from a syringe pump. Beads were then strained, washed twice  
70 by deionized water and then left to dry **at ambient** temperature overnight.

71

72

73

74 Table 1. Compositions and Variables of Formulation of Different formulae.

<b>FORMULA CODE</b>	<b>SODIUM ALGINATE CONC. (% W/V)</b>	<b>CROSS- LINKER CONC. (% W/V)</b>	<b>CROSS- LINKING TIME (MIN)</b>	<b>CROSS- LINKER VOL. : GEL VOL. (ML)</b>	<b>DRUG : POLYMER RATIO</b>
<b>F1</b>	5	1	30	2:1	1:1
<b>F2</b>	2.5	1	30	2:1	1:1
<b>F3</b>	1.67	1	30	2:1	1:1
<b>F4</b>	1	0.5	30	2:1	1:1
<b>F5</b>	1	1	30	2:1	1:1
<b>F6</b>	1	2	30	2:1	1:1
<b>F7</b>	1	1	10	2:1	1:1
<b>F8</b>	1	1	20	2:1	1:1
<b>F9</b>	1	1	60	2:1	1:1
<b>F10</b>	1	1	120	2:1	1:1
<b>F11</b>	1	1	30	1:1	1:1
<b>F12</b>	1	1	30	3:1	1:1
<b>F13</b>	1	1	30	2:1	1:2
<b>F14</b>	1	1	30	2:1	2:1

75  
76  
77  
78  
79

## 80 **2.2.2 Determination of drug load percentage and encapsulation efficiency**

81 The process of determining percentage of drug loaded was done utilizing extraction of the  
82 drug from beads as mentioned by Reis and co-workers with little modification [16]. Specific  
83 weight of beads was taken and crushed. The crushed beads were then placed in a vial and a  
84 proper amount of deionized water was added to it. The vials containing crushed beads and  
85 water were shaken for 15 minutes for complete extraction of drug. The aliquot containing the  
86 drug was then analyzed for gabapentin using the method published by Zour et al. [17], The  
87 mobile phase was prepared in the ratio of 55:35:10 (water:methanol:acetonitrile). The flow  
88 was 1 mL/minute; the injected volume of all samples was 20  $\mu$ L; and The UV detector was  
89 set to detect samples at 210 nm.

90 The percentage drug load was given by the formula:

$$91 \% \text{ Drug load} = (W_{t_{Dg}} / W_{t_{Bd}}) \times 100$$

92 Where,  $W_{t_{Dg}}$  is the amount of drug loaded in beads and  $W_{t_{Bd}}$  is the weight of beads

93 While Encapsulation efficiency of the drug was given by the formula:

$$94 \text{ Percent encapsulation efficiency (EE)} = (W_{t_{Dg}} / W_{t_{Th}}) \times 100$$

95 Where,  $W_{t_{Dg}}$  is the amount of drug loaded in beads  $W_{t_{Th}}$  is the amount of the drug assumed  
96 to be present theoretically in the weight of beads used.

97

## 98 **2.2.3 Determination of swelling index**

99 Swelling index of beads was determined according to the method described by  
100 Pongjanyakul and Puttipipatkachorn [18]. A weight of approximately 100 mg of beads was  
101 taken and placed in a vessel. 14 ml of testing medium were added to the beads. After  
102 predetermined time intervals, all beads were withdrawn from the vessel, carefully and quickly  
103 dried and then weighed. The swelling index was then calculated using the following formula:

$$104 \text{ Swelling index (S.I.)} = [(W_t - W_o) / W_o] \times 100$$

105 Where,  $W_t$  is the weight of beads determined at time t and  $W_o$  is the weight of beads  
106 determined before immersion of beads in testing medium.

107 Two testing media were used in this test, 0.1 N HCl solution; and 0.01 N HCl solution  
108 containing 0.2% of NaCl and 0.25% SLS to simulate gastric fluid without enzymes in fasting  
109 state and in fed state, respectively [19].

110

## 111 **2.2.4 Determination of mucoadhesive properties**

112 The mucoadhesive properties of the beads were evaluated employing the method described  
113 by Lehr et al. [20] with modification. The apparatus used was disintegration tester.

114

### 115 **2.1.4.1 Tissue Preparation:**

116

117 A pig's intestine excised freshly within the first hour of slaughtering was cut longitudinally  
118 and evacuated from its contents. The empty and flattened intestine was then washed  
119 carefully with water and divided into several segments. Tissue segments were then put in zip  
120 bags and are kept frozen at -15 °C. When needed, tissue segment(s) was/were taken out of  
121 the freezer and kept in the refrigerator 24 hrs prior to performing the mucoadhesive  
122 properties testing.

123

### 124 **2.1.4.2 Apparatus Preparation**

125 A piece of the pig's intestine was cut to be as long as a microscopic slide. This piece was  
126 then made to be fixed tightly to the microscopic slide using paper clips, the microscopic slide

127 was designed to be hanged in a disintegration apparatus and during the test it was set to go  
128 up and down in the test solution.

129 The water bath of the disintegration apparatus was filled with testing solution and the  
130 temperature was adjusted to be 37°C. The volume of the solution in the water bath was  
131 adjusted so that at highest point of movement of the apparatus, slide didn't get out of the  
132 testing solution and at lowest point, it didn't touch the bottom. This was done to make the  
133 movement of the test solution in relation to the slide smooth and not turbulent.

134 As in testing the swelling index of the beads, two test media were used in this experiment,  
135 0.1 N HCl solution; and 0.01 N HCl solution containing 0.2% of NaCl and 0.25% SLS to  
136 simulate gastric fluid without enzymes in fasting state and in fed state, respectively [19].

137


#### 138 **2.1.4.3 Performing Test:**

139 The mucosal surface of the intestinal piece was irrigated with some of the test media to  
140 simulate the real conditions. 30 beads were then put randomly on the mucosal surface of the  
141 pig's intestine piece. A weight of 50 grams was put on the beads for 30 seconds, then the  
142 load was removed and the slide containing the intestinal piece loaded with the beads was  
143 hanged on the disintegration apparatus as shown in figure 1.

144 The apparatus was turned on and the piece of pig's intestine, bearing the beads, was  
145 allowed to go in and out of the test media freely.

146 At each time point, the number of beads remaining adhering to the mucosal surface of the  
147 hanged piece of pig's intestine was counted and the number is expressed as a percentage  
148 of the total number of the beads loaded on the intestinal piece.

149



150

151 **Fig. 1. Mucoadhesion testing showing pig's intestine fixed to a slide and beads**  
152 **adhering to it.**

153

#### 154 **2.2.5 Determination of in-vitro release profile**

155 In-vitro drug release study was performed in a simulated acidic environment in fasting and  
156 fed conditions of the stomach [19].

157 The release of gabapentin from alginate beads was done using the procedure published by  
158 Pasparakis and Bouropoulos [21]. An accurately weighed amount of the beads was placed

159 in vials each containing 15 mL of dissolution media pre-warmed up in a shaking water bath  
160 at 37±0.5°C. The speed of shaking was adjusted to be 50 rpm. Samples of the dissolution  
161 media were withdrawn from each vial and replaced by equivalent amount of fresh dissolution  
162 media pre-warmed to 37±0.5°C. Samples withdrawn were analyzed using HPLC method  
163 previously mentioned above [17].  
164

165

#### **2.2.6 Preparation of solid dispersion:**

166 Ethylcellulose (100 cps, Aqualon, Wilmington, DE, USA) was dissolved in absolute ethyl  
167 alcohol and then the clear solution was levigated with the proper amount of the drug. The  
168 formed paste was then continued to be stirred using a pestle till all alcohol used was  
169 evaporated leaving fine and ground powder of Gabapentin-ethylcellulose solid dispersion.  
170 The powder was then left for drying over night to assure the complete evaporation of alcohol  
171 and dryness of the solid dispersion powder.  
172

173  
174

#### **2.2.7 Statistical analysis**

175 Data are presented as means±SE. For group comparisons, the one-way layout ANOVA with  
176 duplication was applied. Significant differences in mean values were evaluated by Student's  
177 unpaired t test. A p value of <0.05 was considered statistically significant.  
178


179

### **3. RESULTS AND DISCUSSION**

180  
181


#### **3.1 Drug load and encapsulation efficiency (EE)**

182  
183 Figures 2 and 3 show the percentage drug load and encapsulation efficiency (EE) of the  
184 prepared alginate formulae. It was shown that, regarding drug loading capacity, increasing  
185 gel concentration, increasing drug/polymer ratio resulted in increasing percent drug load.  
186 Decreasing concentration of cross linker, decreasing time of cross linking and/or reducing  
187 volume of cross linking solution also resulted in increasing percent drug load. This agreed to  
188 results mentioned by Silva and co-workers showing that increasing alginate concentration  
189 lead to a consequent increase in EE [22]. Das and Maurya mentioned the same results in  
190 previous study [13]. This might be attributed to reduced amount of drug that is lost from  
191 beads during cross linking [23,24]. Encapsulation efficiency also depended on the amount of  
192 drug lost during cross linking, therefore, the effect of the gel concentration, concentration of  
193 cross linker, time of cross linking, volume of cross linking solution on EE would resemble that  
194 on drug load. However, regarding drug/polymer ratio, the amount of drug lost during cross  
195 linking is not the only determining factor. A comparison between formulae F13, F5, F14  
196 revealed that increasing drug/polymer ratio resulted in increasing percent drug load and  
197 decreasing EE. These results agreed to results published by Belgamwar et al. [25]. This is  
198 suggested to be attributed to the fact that increasing drug/polymer ratio result in increasing  
199 the amount of drug in the beads (drug load) and at the same time increasing the amount of  
200 drug lost during cross linking (thus reducing the amount of drug existing in beads as  
201 compared to the originally incorporated amount, i.e., reducing EE).  
202



203

204 **Fig. 2. Percentage drug load of formulae F1 – F14. Each data point represents mean  $\pm$**   
 205 **S.E. (n=3).**  
 206



207

208 **Fig. 3. Encapsulation efficiency of formulae F1 – F14. Each data point represents**  
 209 **mean  $\pm$  S.E. (n=3).**

210

211 **3.2 Swelling index**

212


213

214

215


Figures 4 and 5 show swelling index of the prepared alginate formulae after 30 minutes and 120 minutes in fasting and fed-simulated conditions. It was shown that swelling ratio of beads increases as alginate gel concentration decreases, drug/polymer ratio increases, cross linker concentration decreases and/or time of cross linking decreases. **These results**

216 agreed to a previous study done by Roy et al. [26]. It was also shown by Ramesh Babu and  
 217 co-workers that increasing the concentration of cross linker solution has led to a decrease in  
 218 the water uptake by sodium alginate–methylcellulose blend microspheres [27]. This  
 219 observation may be attributed to the fact that increasing calcium ions concentration in the  
 220 cross linking solution leads to formation of the “egg-box” structure of calcium alginate [2] with  
 221 smaller cavities which accommodate less amount of water and hence decreasing water  
 222 retained by alginate and SI of beads. This can be also explained on the basis of Flory’s  
 223 theory of swelling [28]. According to this theory, the swelling ratio of a network (Q) can be  
 224 described by the following equation:  
 225  $Q^{5/3} = \{ [(i/2VN.S^{3/2}) + (1/2 - X_i)/V_i] / V_e/V_o \}$   
 226 where  $i/VN$  is the concentration of the fixed charges referred to unswollen network, S is the  
 227 ionic concentration in the external solution,  $(1/2 - X_i)/V_i$  is the affinity of matrix for water, and  
 228  $V_e/V_o$  is the cross link density of network.  
 229 Volume of cross linking solution had no effect on the swelling of alginate beads. Swelling of  
 230 beads in fed-simulated conditions was shown to be higher than in fasting-simulated ones,  
 231 which was also reported in many cases [10,29].  
 232



233 Fig. 4. Swelling indices of formulae F1 – F14 after 30 and 120 minutes in fasting-  
 234 simulated conditions. Each data represent mean ± S.E. (n=3).  
 235  
 236






237  
238  
239  
240

**Fig. 5. Swelling indices of formulae F1 – F14 after 30 and 120 minutes in fed-simulated conditions. Each data represent mean  $\pm$  S.E. (n=3).**

### 241 3.3 Mucoadhesion properties

242 Figures 6 and 7 show mucoadhesion of the prepared alginate formulae after 1 and 8 hrs in  
 243 fasting and fed-simulated conditions, respectively. It was shown that mucoadhesion of beads  
 244 decreases as alginate gel concentration decreases, drug/polymer ratio increases, cross  
 245 linker concentration decreases and/or time of cross linking decreases. It has been reported  
 246 by Chickering and Mathiowitz that surface charge density plays an important role in  
 247 mucoadhesion. They also reported that polyanionic polymers, such as alginate, are more  
 248 efficient than polycationic or nonionic polymers in mucoadhesion [30]. Increasing degree of  
 249 cross linking resulted in reducing the surface negative charge on the alginate beads resulting  
 250 in decreasing efficiency of mucoadhesion. It was shown also that volume of cross linking  
 251 solution had no effect on the swelling of alginate beads. Formula F4 (corresponding to cross  
 252 linker concentration of 0.5 %) and formula F7 (corresponding to cross linking time of 10  
 253 minutes) showed a way less mucoadhesion after 8 hrs as compared to other formulae. This  
 254 is attributed to the increase in weight of beads prepared according to these formulae to a  
 255 high extent as compared to other formulae. This is shown in SI study (c.f. figures 4 and 5).  
 256




257

258 Fig. 6. Mucoadhesion of formulae F1 – F14 after 1 and 8 hrs in fasting-simulated  
 259 conditions. Each data represents mean  $\pm$  S.E. (n=3).

260

261



262

263

264

265

262 Fig. 7. Mucoadhesion of formulae F1 – F14 after 1 and 8 hrs in fed-simulated  
 263 conditions. Each data represents mean  $\pm$  S.E. (n=3).

### 3.4 Drug release profile

267 Table 2 shows the time at which alginate formulae released 50% and 90% of their drug  
 268 content. It was shown that the rate of drug release from alginate system was retarded as the  
 269 concentration of alginate gel was increased; the drug/polymer ratio was reduced, cross linker  
 270 concentration was increased and/or cross linking time was increased. This is suggested to  
 271 be attributed to the increased viscosity of alginate [31] and/or increased degree of cross  
 272 linking [32]. Rokhade and co-workers studied polymer network microspheres and reported  
 273 that increasing drug/polymer ratio resulted in faster drug release from the microspheres [33].  
 274 It was shown also that release in fed-simulated conditions was faster than that in fasting-  
 275 simulated ones. Formulae showing high swelling index showed also a fast release of the  
 276 drug and vice versa. This is attributed to the fact that swelling index of beads is indicative for  
 277 the interaction between beads and media. The more the interaction between beads and  
 278 media is, the more the beads swell.

279  
280  
281 **Table 2.  $T_{50}$  and  $T_{90}$  of drug release from alginate formulae**

	Fasting Conditions		Fed Conditions	
	$T_{50}^*$ (min)	$T_{90}^{**}$ (min)	$T_{50}^*$ (min)	$T_{90}^{**}$ (min)
<b>F1</b>	98.63 ± 2.38	211.00 ± 7.56	89.38 ± 2.38	198.33 ± 12.76
<b>F2</b>	81.73 ± 2.08	180.20 ± 14.57	76.75 ± 2.30	162.90 ± 14.20
<b>F3</b>	63.67 ± 2.71	129.50 ± 3.35	50.00 ± 1.85	102.41 ± 6.68
<b>F4</b>	17.63 ± 0.57	37.41 ± 1.89	16.91 ± 0.85	33.28 ± 1.22
<b>F5</b>	42.47 ± 1.81	100.18 ± 4.04	35.01 ± 1.73	85.02 ± 2.71
<b>F6</b>	66.48 ± 2.31	121.30 ± 3.77	49.30 ± 1.70	118.65 ± 6.54
<b>F7</b>	20.32 ± 0.52	49.38 ± 3.80	20.50 ± 1.80	44.88 ± 2.07
<b>F8</b>	33.82 ± 1.86	78.70 ± 3.66	30.60 ± 1.51	71.87 ± 3.43
<b>F9</b>	61.74 ± 2.38	121.35 ± 3.99	49.28 ± 2.32	98.58 ± 5.90
<b>F10</b>	65.62 ± 1.61	117.95 ± 4.51	53.73 ± 3.36	108.03 ± 2.89
<b>F11</b>	45.59 ± 0.95	86.03 ± 2.13	35.75 ± 1.37	79.48 ± 3.05
<b>F12</b>	51.95 ± 1.56	92.73 ± 3.78	31.87 ± 1.96	78.68 ± 2.57
<b>F13</b>	40.20 ± 1.62	122.09 ± 1.70	39.94 ± 1.82	103.50 ± 1.49
<b>F14</b>	27.13 ± 2.42	73.90 ± 2.21	51.67 ± 15.37	66.63 ± 3.20

282

283

284

285

\*  $T_{50}$  is the time at which 50% of the drug was released from the beads

\*\*  $T_{90}$  is the time at which 90% of the drug was released from the beads

### 3.5 Seeking for an optimal formulation

286 Table 3 shows a summary of the studied factors and their effect on the properties of alginate  
 287 beads. An optimized formula (OF) was suggested so that the effects of formulation factors  
 288 can be compensated. It was shown from figures 8-12 that the percent drug load, EE, SI and  
 289 mucoadhesion of OF formula were accepted for targeting and delivering gabapentin to the  
 290 upper duodenal region. However, OF formula showed fast release that is not suitable for  
 291 sustaining the release of the drug as shown in figures 13,14. Controlling drug release from  
 292 alginate beads was attempted using SDS [33] and solid dispersion [34]. The compositions of  
 293 OF, SDSF, SDF and FSF formulae are shown by table 4. SDSF formula showed inferior  
 294 properties as compared to all other formulae. It was shown that incorporating SDS into gel  
 295 beads has facilitated the release of drug during both cross linking process and drug release

296 study. This resulted in reduction of the percent drug load and encapsulation efficiency; and  
 297 improper sustained release drug delivery system profile. The use of solid dispersion for  
 298 sustain the release of the drug had no effect on the targeting properties of alginate beads but  
 299 sustained the release of the drug to a great degree. To obtain a very fast release and a  
 300 sustained one, the drug incorporated into beads was divided into two portions, the first  
 301 portion (1/3 of the total amount) is free drug to produce a fast release and the second portion  
 302 (2/3 of the total amount) was solid dispersion to sustain the release of the drug. The release  
 303 of this system, as shown in figure 10, exhibited a fast release (almost 33% during the first  
 304 half an hour) and sustained release during the rest of the 10 hrs.

305  
 306 **Table 3. summary of the studied factors and their effect on the properties of alginate**  
 307 **system.**


	Drug Load	Encapsulation Efficiency	Swelling Index	Mucoadhesion		Release Rate
				1st	2nd	
<b>Conc. Of Alginate</b>	+ *	+	- **	-	+	-
<b>Conc. Of CaCl<sub>2</sub></b>	-	-	-	-	+	-
<b>Time of Cross Linking</b>	-	-	-	-	+	-
<b>VDps : VCLS</b>	-	-	N †	N	N	N
<b>Drug:Polymer Ratio</b>	+	-	± ‡	±	±	+

308  
 309 \* Inversely Related  
 310 \*\* Directly Related  
 311 † Not Related  
 312 ‡ Increase to certain Limit or beyond Certain Limit  
 313

314 **Table 4. Compositons and Formulation Variables of Modified Alginate Formulae**


Formula Code	Sodium Alginate Concentration (% W/V)	Cross Linking Solution Concentration (% W/V)	Cross Linking Time (min)	Cross-Linking solution Volume : Gel Volume	Drug : polymer Ratio	SDS (g)	Free Drug (%) of the Total Amount of Drug Added	Drug-EC Solid Dispersion (% of the Total Amount of Drug Added)
OF *	2	1	30	1:1	3:2	-	-	-
SDSF **	2	1	30	1 : 1	3 : 2	3	100	0
SDF †	2	1	30	1 : 1	3 : 2	-	0	100
FSF ‡	2	1	30	1 : 1	3 : 2	-	33.33	66.67

315 \* Optimized formula  
 316 \*\* SDSF sodium dodecyl sulfate formula  
 317 † solid dispersion formula  
 318 ‡ finally suggested formula




319  
320  
321  
322  
323

**Fig. 8. Drug load and encapsulation efficiency of formulae OF, SDSF, SDF and FSF. Each data represents mean  $\pm$  S.E. (n=3).**




324  
325  
326  
327

**Fig. 9. Swelling ratio of formulae OF, SDSF, SDF and FSF after 30 and 120 minutes in fasting-simulated conditions. Each data represents mean  $\pm$  S.E. (n=3).**




328  
329  
330  
331  
332

Fig. 10. Swelling ratio of formulae OF, SDSF, SDF and FSF after 30 and 120 minutes in fed-simulated conditions. Each data represents mean  $\pm$  S.E. (n=3).




333  
334  
335  
336

Fig. 11. Mucoadhesion of formulae OF, SDSF, SDF and FSF after 1 and 8 hrs in fasting-simulated conditions. Each data represents mean  $\pm$  S.E. (n=3).




337  
338  
339  
340  
341

Fig. 12. Mucoadhesion of formulae OF, SDSF, SDF and FSF after 1 and 8 hrs in fed-simulated conditions. Each data represents mean  $\pm$  S.E. (n=3).



342  
343  
344  
345

Fig. 13. Drug release profiles of formulae OF, SDSF, SDF and FSF in fasting-simulated conditions. Each data represents mean  $\pm$  S.E. (n=3).



346  
347 **Fig. 14. Drug release profiles of formulae OF, SDSF, SDF and FSF in fed-simulated**  
348 **conditions. Each data represents mean  $\pm$  S.E. (n=3).**  
349

350 The dissolution efficiency (D.E.), which is a suitable comparative parameter for the  
351 quantification of dissolution data, was utilized to assess the effect of alginate modification on  
352 the dissolution rate of the drug [35]. It was calculated according to the equation mentioned  
353 by Khan and Rhodes [35] as follows,  
354

355 Dissolution Efficiency (D.E.) = 
$$\frac{\int_0^t y \cdot dt}{y_{100} \cdot t}$$
  
356

357 Dissolution efficiencies of optimized formulae are given by table 5. The DE0-60min for OF,  
358 SLSF, SDF and FSF formulae were shown to be 265.68, 258.54, 7.06 and 8.48,  
359 respectively. It was shown from the values of DE of OF, SDSF, SDF and FSF formulae that  
360 incorporating SDS into alginate beads had insignificant effect on retarding drug release.  
361 However, the use of EC solid dispersion retarded the release of gabapentin from alginate  
362 beads significantly.  
363

364 **Table 5. Dissolution efficiency of modified formulae.**

	Fasting-Simulated Conditions				
	0.5 h	1 h	2 h	3 h	4 h
<b>OF</b>	135.28	256.68	1047.02	1200.02	1241.19
<b>SDSF</b>	114.71	258.64	1117.11	1228.84	1249.87
<b>SDF</b>	2.45	7.06	9.04	10.71	25.15
<b>FSF</b>	3.23	8.48	10.57	12.31	28.26
	Fed-Simulated Conditions				
	0.5 h	1 h	2 h	3 h	4 h
<b>OF</b>	324.77	489.75	1227.81	1252.57	1254.92
<b>SDSF</b>	296.03	481.47	1233.39	1250.96	1252.11
<b>SDF</b>	3.28	8.81	10.74	12.48	28.64
<b>FSF</b>	3.66	9.74	11.98	13.74	30.67



365 **4. CONCLUSION**

366 The optimized formula, OF formula, has shown acceptable drug load, encapsulation  
367 efficiency, swelling index and mucoadhesion but not sustained gabapentin release profile  
368 ,i.e. alginate system is not capable of fulfilling requirements of producing gabapentin  
369 sustained release dosage form (spatial placement and temporal delivery) by just adjusting  
370 formulation variables.

371 Incorporating SDS released gabapentin even faster than OF formula. It also reduced  
372 targeting capabilities of alginate system as indicated by fast detachment of beads from  
373 intestine piece during mucoadhesion testing.

374 Incorporating solid dispersion of EC with gabapentin in alginate beads instead of free drug  
375 retarded the release of gabapentin from alginate beads successfully. Ethylcellulose -  
376 gabapentin solid dispersion also increased the drug load and EE with minor positive impact  
377 on the mucoadhesion capabilities of alginate beads.

378 A finally optimized formula has been suggested by incorporating a combination of solid  
379 dispersion and free gabapentin in the ratio of 1:2 in alginate system to achieve burst release  
380 of gabapentin and hence fast effect (33.417%  $\pm$  2.087 of gabapentin was released during the  
381 first 30 minutes in fasting-simulated conditions) and sustained release and hence maintained  
382 effect (after 6 hrs, only 91.217%  $\pm$  2.523 of gabapentin was released).

383

384 **ACKNOWLEDGEMENTS**

385

386 Authors would like to acknowledge the Egyptian Government, Suez Canal University (Egypt)  
387 and Creighton University (USA) for the scholarship and financial assistance

388

389

390

391 **AUTHORS' CONTRIBUTIONS**

392

393 "All authors read and approved the final manuscript."

394

395

396 **REFERENCES**

397

398 1. Chitnis, CE, Ohman, DE. Cloning of *Pseudomonas aeruginosa* algG, which controls  
399 alginate structure. *J. Bacteriol.* 1990;172(6):2894-2900.

400 2. Aslani, P, Kennedy, RA. Effect of gelation condition and dissolution media on the  
401 release of paracetamol from alginate gel beads. *J. Microencapsul.* 1996;13:601-  
402 614.

403 3. Batyrbekov, EO, Iskakov, RM, Boldyrev, DY, Yu, VK, Dzhumagulova, ZKh, Praliev,  
404 KD, Zhubanov, BA, Berlin, KD. Controlled delivery of analgetics from calcium  
405 alginate beads. *Materials Res. Society Symposium Proceeding, PA, USA.*  
406 2004;EXS-1:14.4.1-14.4.4.

407 4. Aggarwal, N, HogenEsch, H, Guo, P, North, A, Suckow, M, Mittal, SK.  
408 Biodegradable alginate microspheres as a delivery system for naked DNA. *Can. J.*  
409 *Vet. Res.* 1999;63:148-152.

410 5. Barrias, CC, Lamghari, M, Granja, PL, Sá Miranda, MC, Barbosa, MA. Biological  
411 evaluation of calcium alginate microspheres as a vehicle for the localized delivery of  
412 a therapeutic enzyme. *J. Biomed. Material Res.* 2005;74A(4):545-552.

413 6. Zhu, H, Srivastava, R, Brown, JQ, McShane, MJ. Combined physical and chemical  
414 immobilization of glucose oxidase in alginate microspheres improves stability of  
415 encapsulation and activity. *Bioconjugate Chem.* 2005;16:1451-1458.

- 416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467
7. Seo, JY, Seung, Y, Ahn, BY, Kwon, IC, Chung, H, Jeong, SY. Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesion A encapsulated in microspheres. *Infect. Immun.* 2002;70(3):1143-1149.
  8. Sailaja, G, HogenEsch, H, North, A, Hays, J, Mittal, SK. Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector specific immune response. *Gene Ther.* 2002;9(24):1722–1729.
  9. Chickering, DE, Jacob, JS, Desai, TA, Harrison, M, Harris, WP, Morrell, CN, Chaturvedi, P, Mathiowitz, E. Bioadhesive microspheres: III. An in vivo transit and bioavailability study of drug-loaded alginate and poly(fumaric-co-sebacic anhydride) microspheres. *J. Control. Release.* 1997;48:35-46.
  10. Takka, S, Ocak, ÖH, Acartürk, F. Formulation and investigation of nicardipine HCl–alginate gel beads with factorial design-based studies. *Eur. J. Pharm. Sci.* 1998;6:241–246.
  11. Al-Kassas, RS, Al-Gohary, OMN, Al-Faadhel, MM. Controlling of systemic absorption of gliclazide through incorporation into alginate beads. *Int. J. Pharm.* 2007;341:230-237.
  12. Prajapati, SK, Tripathi, P, Ubaidulla, U, Anand, V. Design and development of gliclazide mucoadhesive microcapsules: in vitro and in vivo evaluation. *AAPS PharmSciTech* 2008;9(1):224-230.
  13. Das, MK, Maurya, DP. Evaluation of diltiazem hydrochloride-loaded mucoadhesive microspheres prepared by emulsification and internal gelation technique. *Acta Poloniae Pharmaceutica - Drug Res.* 2008;65(2):249-259.
  14. Michael, J, McLean, MD, Gidal, BE. Gabapentin dosing in the treatment of epilepsy. *Clinical Therapeutics* 2003;25(5):1382-1406.
  15. Stewart, BH, Kugler, AR, Thompson, PR, Bokbrader, HN. A Saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. *Pharm. Res.* 1993;10(2):276-281.
  16. Reis, CP, Ribeiro, AJ, Neufeld, RJ, Veiga, F. Alginate microparticles as novel carrier for oral insulin delivery. *Biotech. Bioeng.* 2007;96(5):977-989.
  17. Zour, E, Lodfi, SA, Nusbett, RU, Silbering, SB, Shaturvedi, PR. Stability studies of gabapentin in aqueous solutions. *Pharm. Res.* 1992;9(5):595-600.
  18. Pongjanyakul, T, Puttipatkhachorn, S. Xanthan-alginate composite gel beads: Molecular interactions and in vitro characterization. *Int. J. Pharm.* 2007;331:61-71.
  19. Dorożyński, P, Kulinowski, P, Jachowicz, R, Jasiński, A. Development of a system for simultaneous dissolution studies and magnetic resonance imaging of water transport in hydrodynamically balanced systems: A technical Note. *AAPS PharmSciTech* 2006;8(1), Article 15, E1-E4.
  20. Lehr, CM, Bouwstra, JA, Tukker, JJ, Junginger, HE. Intestinal transit of bioadhesive microspheres in an in situ loop in the rat. A comparative study with copolymers and blends based on poly(acrylic acid). *J. Control. Release* 1990;13(1):51-62.
  21. Pasparakis, G, Bouropoulos, N. Swelling studies and in vitro release of verapamil from calcium alginate and calcium alginate–chitosan beads. *Int. J. Pharm.* 2006;323:34–42.
  22. Silva, CM, Ribeiro, AJ, Figueiredo, IV, Gonçalves, AR, Veiga, F. Alginate microspheres prepared by internal gelation: Development and effect on insulin stability. *Int. J. Pharm.* 2006;311:1-10.
  23. Lee, BJ, Min, GH. Oral controlled release of melatonin using polymer-reinforced and coated alginate beads. *Int. J. Pharm.* 1996;144:37-46.
  24. Singhal, P, Kumar, K, Pandey, M, Saraf, SA. Evaluation of acyclovir loaded oil entrapped calcium alginate beads prepared by ionotropic gelation method. *Int. J. Chem. Tech. Res.* 2010;2(4):2076-2085.

- 468 25. Belgamwar, V, Shah, V, Saurana, SJ. Formulation and evaluation of oral  
469 mucoadhesive multiparticulate system containing metoprolol tartarate: An in vitro –  
470 ex vivo characterization. *Curr. Drug Deliv.* 2009;6:113-121
- 471 26. Roy, A, Bajpai, J, Bajpai, AK. Development of calcium alginate-gelatin based  
472 microspheres for controlled release of endosulfan as a model pesticide. *Indian J.*  
473 *Chem. Tech.* 2009;17:388-395.
- 474 27. Babu, VR, Sairam, M, Hosamani, KM, Aminabhavi, TM. Preparation of sodium  
475 alginate-methylcellulose blend microspheres for controlled release of nifedipine.  
476 *Carb. Pol.* 2007;69:241–250.
- 477 28. Flory, PJ, Rehner Jr., J. Statistical mechanics of cross-linked polymer networks. II.  
478 Swelling. *J. Chem. Phys.* 1943;11:521-526.
- 479 29. Segi, N, Yotsuyanagi, T, Ikeda, K. Interaction of calcium-induced alginate gel beads  
480 with propranolol. *Chem. Pharm. Bull.* 1989; 37(11):3092–3095. Cited after: Takka,  
481 S, Ocak, ÖH, Acartürk, F. Formulation and investigation of nicardipine HCl–alginate  
482 gel beads with factorial design-based studies. *Eur. J. Pharm. Sci.* 1998;6:241-246.
- 483 30. Chickering, DE, Mathiowitz, E. Bioadhesive microspheres: I. A novel electrobalance-  
484 based method to study adhesive interactions between individual microspheres and  
485 intestinal mucosa *J. Control. Release* 1995;34:251–261.
- 486 31. Tonnesen, HH, and Karlsen, J. Alginate in Drug Delivery Systems. *Drug Dev. Ind.*  
487 *Pharm.* 2002;28:621–630.
- 488 32. Rokhade, AP, Agnihotri, SA, Patil, SA, Mallikarjuna, NN, Kulkarni, PV, Aminabhavi,  
489 TM. Semi-interpenetrating polymer network microspheres of gelatin and sodium  
490 carboxymethyl cellulose for controlled release of ketorolac tromethamine. *Carb. Pol.*  
491 2006;65:243–252.
- 492